Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

ClinicalTrials.gov ID: NCT00006604

Public ClinicalTrials.gov record NCT00006604. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study was to find a safe and tolerable dose of the protease inhibitor (PI) atazanavir (ATV), with or without a low-dose boost of the PI ritonavir (RTV), when taken with other anti-HIV drugs in HIV infected infants, children, and adolescents. Advancements in anti-HIV drugs for HIV infected children and adolescents have been hard to make, in part because these patients often do not take the drugs as prescribed. ATV may be a better option because it is available in the form of powder which children and adolescents may be more willing to take regularly. Using a low dose of RTV as a boosting agent for ATV may also increase the chances of virologic response of highly active antiretroviral treatment (HAART)-experienced patients. This study aimed to find safe and tolerable doses of ATV with or without low-dose RTV boost in infants, children, and adolescents. For this study, participants were enrolled in the United States and South Africa.

Study identification

NCT ID
NCT00006604
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Enrollment
195 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
91 Days to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2000
Primary completion
Sep 30, 2011
Completion
Aug 31, 2014
Last update posted
Nov 4, 2021

2000 – 2014

United States locations

U.S. sites
32
U.S. states
18
U.S. cities
26
Facility City State ZIP Site status
UAB Pediatric Infectious Diseases CRS Birmingham Alabama 35233
Usc La Nichd Crs Alhambra California 91803
University of California, UC San Diego CRS La Jolla California 92093-0672
Miller Children's Hosp. Long Beach CA NICHD CRS Long Beach California 90806
UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS Los Angeles California 900951752
Univ. of California San Francisco NICHD CRS San Francisco California 94143
Univ. of Colorado Denver NICHD CRS Aurora Colorado 80045
Howard Univ. Washington DC NICHD CRS Washington D.C. District of Columbia 20060
South Florida CDTC Ft Lauderdale NICHD CRS Fort Lauderdale Florida 33316
Columbus Regional HealthCare System, The Med. Ctr. Columbus Georgia 31901
Rush Univ. Cook County Hosp. Chicago NICHD CRS Chicago Illinois 60612
Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS Chicago Illinois 60614
Tulane Univ. New Orleans NICHD CRS New Orleans Louisiana 701122699
Univ. of Maryland Baltimore NICHD CRS Baltimore Maryland 21201
Johns Hopkins Univ. Baltimore NICHD CRS Baltimore Maryland 21287
Boston Medical Center Ped. HIV Program NICHD CRS Boston Massachusetts 02118
WNE Maternal Pediatric Adolescent AIDS CRS Worcester Massachusetts 016550001
Rutgers - New Jersey Medical School CRS Newark New Jersey 07103
Nyu Ny Nichd Crs New York New York 10016
Harlem Hosp. Ctr. NY NICHD CRS New York New York 10037
SUNY Upstate Med. Univ., Dept. of Peds. Syracuse New York 13210
Bronx-Lebanon Hospital Center NICHD CRS The Bronx New York 10457
Jacobi Med. Ctr. Bronx NICHD CRS The Bronx New York 10461
DUMC Ped. CRS Durham North Carolina 277103499
Philadelphia IMPAACT Unit CRS Philadelphia Pennsylvania 19104
St. Christopher's Hosp. for Children Philadelphia Pennsylvania 191341095
St. Jude Children's Research Hospital CRS Memphis Tennessee 38105
Children's Med. Ctr. Dallas Dallas Texas 75235
Texas Children's Hospital CRS Houston Texas 77030
Children's Hosp. of the King's Daughters, Infectious Disease Norfolk Virginia 23507
Childrens Hosp. of the Kings Daughters Norfolk Virginia 23507
Seattle Children's Research Institute CRS Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00006604, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 4, 2021 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00006604 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →